ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Abbott Laboratories and Genentech have formed a collaboration for the research, development, and commercialization of two of Abbott's investigational cancer compounds, known as ABT-263 and ABT-869. The small-molecule compounds, discovered by Abbott scientists, are being described as targeted therapies that promise unique approaches to treating cancer. ABT-263 is a Bcl-2 family protein antagonist that restores apoptosis, or cell death, in cancer cells. ABT-869 is a kinase inhibitor that stops tumors from growing by preventing the growth of blood vessels that supply them.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X